BCRX241220P9000
- 1.59
- 0.000.00%
BioCryst Pharmaceuticals Newsroom
BofA Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating
BioCryst Pharmaceuticals Price Target Maintained With a $14.00/Share by Needham
BioCryst Pharmaceuticals Is Maintained at Equal-Weight by Barclays
BioCryst Pharma Analyst Ratings
RBC Capital Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $8 to $30
Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $20
JMP Securities Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $16
Evercore Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Maintains Target Price $10
JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $16
BioCryst Pharmaceuticals Price Target Raised to $7.00/Share From $6.00 by Barclays
A Quick Look at Today's Ratings for BioCryst Pharmaceuticals(BCRX.US), With a Forecast Between $10 to $30
BioCryst Pharmaceuticals: A Buy Rating Anchored on Orladeyo's Success and Expansion in Rare Disease Treatments
BioCryst Pharma Analyst Ratings
HC Wainwright & Co. Reiterates Buy on BioCryst Pharma, Maintains $30 Price Target
BioCryst Pharmaceuticals: Strong Orladeyo Sales and Promising Pipeline Justify Buy Rating
Piper Sandler Maintains BioCryst Pharmaceuticals(BCRX.US) With Buy Rating, Raises Target Price to $20
J.P. Morgan Securities: Maintaining the BioCryst Pharma (BCRX.US) rating, adjusted from superior to superior market rating, and adjusted the target price from $14.00 to $15.00.
JMP Securities Maintains Market Outperform on BioCryst Pharma, Raises Price Target to $15